Fördermittelbescheid für die Biotechnologie-Firma Probiodrug AG
Probiodrug AG Reported on the Results of its Clinical Phase IIa Trial with the DPIV Inhibitor P93/01 in Type 2 Diabetes and its Patent Licensing Programs
Halle (Saale), Germany //
Probiodrug announced today that the company has concluded a single dose clinical trial involving 16 patients. “A preliminary analysis of the data reveals the expected impact on glucose lowering” comments Hans-Ulrich Demuth, Chief Scientific Officer.
Probiodrug AG is a biopharmaceutical company that discovers, develops, and commercializes therapeutic medicines for the treatment of diabetes, obesity and other serious medical conditions based on its detailed understanding of the actions of Dipeptidyl Peptidase IV and related enzymes.
Probiodrug AG
Dr Konrad Glund
Weinbergweg 22
D-06120 Halle (Saale)
Germany
Tel.: +49 345 55599-00
Fax: +49 345 55599-01
Mail: konrad.glund@probiodrug.de